
Thermo Fisher Scientific to Acquire Patheon
Thermo Fisher will acquire Patheon for approximately $7.2 billion, including the assumption of approximately $2 billion of net debt.
On May 15, 2017, Thermo Fisher Scientific announced plans to purchase Patheon for $35 per share in cash. The transaction totals approximately $7.2 billion, which includes the assumption of approximately $2 billion of net debt.
Patheon has a network of facilities, primarily in North America and Europe, and approximately 9000 professionals worldwide. In 2016, Patheon generated approximately $1.9 billion in revenue and will become part of Thermo Fisher's Laboratory Products and Services Segment, the companies said in a
“The combined company's extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities,” the companies noted in a
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.